Members

Dr. Rosenblatt is Senior Partner at Flagship Pioneering in Cambridge, MA. Previously, he served as Chief Medical Officer for Merck from 2009-2016, reporting to the CEO. Prior to that he served as Dean of Tufts University School of Medicine. Before that, he held the Robert Ebert Professorship in Molecular Medicine and then the George R. Minot Professorship of Medicine at Harvard Medical School (HMS). He served as the President of Beth Israel Deaconess Medical Center (BIDMC) from 1999-2001. Previously, he was the Harvard Faculty Dean and Senior Vice President for Academic Programs at BIDMC.

Dr. Rosenblatt has also served as Director of the Harvard-MIT Division of Health Sciences and Technology. Earlier he was Senior Vice President for Research at Merck Research Laboratories where he co-led the development of alendronate (FOSAMAX), now the leading therapy worldwide for osteoporosis. At Merck, he led drug discovery efforts in molecular biology, bone biology, virology, cancer research, gastroenterology, ophthalmology, and cardiovascular research in the United States, Japan, and Italy. He also headed Merck’s worldwide University and Industry Relations Department.
He has served in several roles in Moderna’s coronavirus vaccine efforts: He is a member of Moderna’s Development Committee of the Board and the Vaccine Acceleration Committee. He serves as chairman of the Vaccine Ethics and Access Committee and is a special consultant to Moderna’s chief medical officer.

He is the recipient of the Fuller Albright Award for his work on parathyroid hormone, the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman’s Award from Merck. He has been an active participant in the biotechnology industry, serving on the board of directors and scientific advisory boards of several biotech companies. He was a scientific founder of ProScript, the company that discovered bortezomib (Velcade), now Takeda’s drug for multiple myeloma and other malignancies, and Radius Pharmaceuticals, a women’s health company. He was a member of the Board of Scientific Counselors of the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians, to Fellowship in the American Association for the Advancement of Science and the American College of Physicians, and the presidency of the American Society of Bone and Mineral Research. He has testified before a Senate Hearing on U.S. biomedical research priorities in 1997, and in 2011 as a consultant to the U.S. President’s Council of Advisors on Science and Technology. Currently he is a member of the National Institutes of Health NCATS (National Center for the Advancements of Translational Science) Advisory Board.

Dr. Rosenblatt currently is a member of the Harvard Medical School (HMS) Board of Fellows, the Tufts Graduate School of Biomedical Sciences Dean’s Advisory Committee, and on research advisory committees of the Massachusetts General Hospital, Brigham and Women’s Hospital, and Children’s Hospital (Boston). He also serves on the advisory boards of several academic and non-profit organizations. He is a member of the Board of Directors of Ferring Pharmaceuticals (U.S. Division), Rubius Therapeutics and several biotech start-ups. He currently serves as the President of the Harvard Medical School Alumni Association.
From 1981 to 1984, he served as Chief of the Endocrine Unit, Massachusetts General Hospital. He received his undergraduate degree summa cum laude from Columbia and his M.D. magna cum laude from Harvard. His internship, residency, and endocrinology training were all at the Massachusetts General Hospital.